Histamine dihydrochloride and low-dose interleukin-2 has anti-leukemic efficacy in <i>NPM1</i>-mutated and myelomonocytic/monocytic acute myeloid leukemia

Affiliations

• ¹ TIMM Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden; Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg.
• ² Internal Medicine, Privatklinik Hochrum, Rum.
• ³ Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich.
• ⁴ Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna.
• ⁵ TIMM Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg.
• ⁶ TIMM Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden; Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg. [email protected].